Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.

Autor: Pivot X; Institute of Cancer Strasbourg, Strasbourg, France., Georgievich MA; St Petersburg GBUZ City Clinical Oncology Dispensary, St Petersburg, Russia., Shamrai V; Vinnytsia Regional Clinical Oncological Dispensary, Vinnytsia, Ukraine., Dzagnidze G; S. Khechinashvili University Hospital, Tbilisi, Georgia., Soo Hoo HF; Penang General Hospital, Penang Island, Malaysia., Kaewkangsadan V; Department of Surgery, Phramongkutklao hospital, Bangkok, Thailand., Petrelli F; Oncology Unit, ASST Bergamo Ovest, Trevigilio, Bergamo, Italy., Villanueva C; Clinique Clementville, Montpellier, Montpellier, France., Nikolaevich LO; Republican Clinical Oncology Dispensary of Ministry of Health Bashkortostan Republic, Republic of Russia., Hii J; Prestige BioPharma Ltd, Singapore., Kim J; Prestige BioPharma Ltd, Singapore., Pradhan S; Prestige BioPharma Ltd, Singapore., Jaison L; Prestige BioPharma Ltd, Singapore., Feyaerts P; Prestige BioPharma Ltd, Singapore., Kaufman L; DICE, Naamloze vennootschap, Belgium., Derde MP; DICE, Naamloze vennootschap, Belgium., Bonamy GMC; Prestige BioPharma Ltd, Singapore., Deforce F; DICE, Naamloze vennootschap, Belgium., Cox DG; Institute of Cancer Strasbourg, Strasbourg, France.

Publikováno v: JAMA oncology [JAMA Oncol] 2022 May 01; Vol. 8 (5), pp. 698-705.